Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
Sponsor: Ottawa Hospital Research Institute
Summary
This vanguard pilot study compares rivaroxaban and apixaban, two of the new oral blood thinners for the treatment of blood clots. Half of the patients will receive apixaban and half will receive rivaroxaban. The main objective is to determine the feasibility of patient recruitment and resources required to follow enrolled patients and inform for a larger, multi-centered trial and to assess which one is safer.
Official title: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
71
Start Date
2016-05
Completion Date
2018-02
Last Updated
2026-09-24
Healthy Volunteers
No
Conditions
Interventions
Apixaban
Rivaroxaban
Locations (4)
University of Alberta
Edmonton, Alberta, Canada
Hamilton General Hospital
Hamilton, Ontario, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Hôtel-Dieu de Sherbrooke
Sherbrooke, Quebec, Canada